-
EP3672967
European procedure
Extract from the Register of European Patents
EP About this file: EP3672967
| EP3672967 - AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 12.08.2022 Database last updated on 19.03.2026 | |
| Former | The patent has been granted Status updated on 03.09.2021 | ||
| Former | Grant of patent is intended Status updated on 27.04.2021 | ||
| Former | Request for examination was made Status updated on 09.04.2021 | ||
| Former | Grant of patent is intended Status updated on 09.12.2020 | ||
| Former | Request for examination was made Status updated on 29.05.2020 | ||
| Former | The international publication has been made Status updated on 02.03.2019 | ||
| Former | unknown Status updated on 07.09.2018 | Most recent event Tooltip | 04.11.2022 | Lapse of the patent in a contracting state | published on 07.12.2022 [2022/49] | Applicant(s) | For all designated states Sprint Bioscience AB Hälsovägen 7 141 57 Huddinge / SE | [2020/27] | Inventor(s) | 01 /
LINDSTRÖM, Johan c/o Sprint Bioscience AB Hälsovägen 7 141 57 Huddinge / SE | 02 /
FORSBLOM, Rickard c/o Sprint Bioscience AB Hälsovägen 7 141 57 Huddinge / SE | 03 /
RAHM, Fredrik c/o Sprint Bioscience AB Hälsovägen 7 141 57 Huddinge / SE | 04 /
VIKLUND, Jenny c/o Sprint Bioscience AB Hälsovägen 7 141 57 Huddinge / SE | [2020/27] | Representative(s) | McNab, Donald C. Marks & Clerk LLP 40 Torphichen Street Edinburgh EH3 8JB / GB | [N/P] |
| Former [2020/27] | AWA Sweden AB P.O. Box 45086 104 30 Stockholm / SE | Application number, filing date | 18759307.4 | 23.08.2018 | [2020/27] | WO2018EP72785 | Priority number, date | EP20170187519 | 23.08.2017 Original published format: EP 17187519 | [2020/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019038384 | Date: | 28.02.2019 | Language: | EN | [2019/09] | Type: | A1 Application with search report | No.: | EP3672967 | Date: | 01.07.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.02.2019 takes the place of the publication of the European patent application. | [2020/27] | Type: | B1 Patent specification | No.: | EP3672967 | Date: | 06.10.2021 | Language: | EN | [2021/40] | Search report(s) | International search report - published on: | EP | 28.02.2019 | Classification | IPC: | C07D471/04, A61K31/437 | [2020/27] | CPC: |
C07D471/04 (EP,CN,IL,KR,US);
A61K31/444 (IL,KR,US);
A61K31/4545 (IL,US);
A61K31/496 (EP,IL,KR,US);
A61K31/506 (IL,US);
A61K31/5377 (IL,US);
A61K38/45 (IL,US);
A61N5/10 (IL,US);
A61P25/00 (CN);
A61P29/00 (CN);
A61P31/12 (CN);
A61P35/00 (EP,CN,KR,US);
A61P35/02 (CN);
A61P37/00 (CN);
A61P37/06 (CN);
A61P9/00 (CN)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/27] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | AZAINDOLYLPYRIDON- UND DIAZAINDOLYLPYRIDONVERBINDUNGEN | [2020/27] | English: | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | [2020/27] | French: | AZAINDOLYLPYRIDONE ET COMPOSÉS DIAZAINDOLYLPYRIDONE | [2021/01] |
| Former [2020/27] | COMPOSÉS D'AZAINDOLYLPYRIDONE ET DE DIAZAINDOLYLPYRIDONE | Entry into regional phase | 20.03.2020 | National basic fee paid | 20.03.2020 | Designation fee(s) paid | 20.03.2020 | Examination fee paid | Examination procedure | 20.03.2020 | Amendment by applicant (claims and/or description) | 20.03.2020 | Examination requested [2020/27] | 20.03.2020 | Date on which the examining division has become responsible | 10.12.2020 | Communication of intention to grant the patent | 07.04.2021 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 28.04.2021 | Communication of intention to grant the patent | 27.08.2021 | Fee for grant paid | 27.08.2021 | Fee for publishing/printing paid | 27.08.2021 | Receipt of the translation of the claim(s) | Divisional application(s) | EP21196341.8 / EP4001278 | Opposition(s) | 07.07.2022 | No opposition filed within time limit [2022/37] | Fees paid | Renewal fee | 16.07.2020 | Renewal fee patent year 03 | 15.07.2021 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 06.10.2021 | [2022/49] | Cited in | International search | [AD] WO2015108881 (MILLENNIUM PHARM INC et al.) | [A] WO2010003133 (EXELIXIS INC et al.) | by applicant | WO2013076501 | WO2015150555 | WO2015150557 | WO2015108861 | WO2015108881 | WO2012085815 | WO2012085244 | WO2013190510 | AMARAVADI ET AL., CLIN CANCER RES., vol. 17, 2011, pages 654 - 666 | CARPENTIER ET AL., TRAFFIC, 2013 | BACKER ET AL., J BIOCHEM., vol. 410, 2008, pages 1 - 17 | BOYA ET AL., NAT CELL BIOL, vol. 15, 2013, pages 713 - 720 | NAGELKERKE ET AL., SEMIN CANCER BIOL, vol. 31, 2014, pages 99 - 105 | LEONE ET AL., TRENDS IN ENDOCRIN METAB, vol. 24, 2013, pages 209 - 217 | DOWDLE ET AL., NAT CELL BIOL, vol. 16, 2014, pages 1069 - 79 | NEMAZANYY, NATURE COMMUN, vol. 6, 2015, pages 8283 | RUBINSZTEIN ET AL., NAT REV, vol. 11, 2012, pages 709 - 730 | FARKAS, J. BIOL. CHEM., vol. 286, no. 45, 2011, pages 38904 - 12 | T.W. GREENE; P.G.M WUTZ: "Protective Groups in Organic Synthesis", 2006, WILEY-INTERSCIENCE |